Outcomes of Kawasaki disease with giant coronary aneurysms: a single-centre study in southwest China

医学 川崎病 心肌梗塞 动脉瘤 内科学 心脏病学 冠状动脉瘤 动脉 血栓形成 冠状动脉血栓形成 右冠状动脉 外科 冠状动脉造影
作者
Piaoliu Yuan,Danyan Su,Krishna Deo Mandal,Suyuan Qin,Na Zhao,Yusheng Pang
出处
期刊:Cardiology in The Young [Cambridge University Press]
卷期号:30 (6): 834-839 被引量:6
标识
DOI:10.1017/s1047951120001134
摘要

Abstract Background: Giant coronary aneurysms are the most severe complications of Kawasaki disease. There are few reports of outcomes from China. Most previous studies were based only on absolute aneurysmal dimensions. The aim of the present study was to catalog the outcomes of Kawasaki disease with giant coronary aneurysms in southwest China based on absolute dimensions and the z-score adjusted for body surface area. Methods and results: All patients diagnosed with giant coronary aneurysms (z-score ≥ 10 or absolute dimension ≥ 8 mm) between December, 2002 and December, 2018 were included. We retrospectively analysed patient characteristics and clinical data from 38 patients with giant coronary aneurysms. Over a median follow-up period of 30.5 months (range from 1.7 months to 22.3 years), including patients in chronic phase who had been diagnosed prior to 2002, eight patients had myocardial infarction, including two deaths and one patient with coronary artery bypass grafting. The 1-, 2-, and 5-year event-free rates were 0.63, 0.63, and 0.53 for thrombosis, respectively, and 0.86, 0.81, and 0.81 for major adverse cardiac events, respectively. The 1-, 2-, and 5-year regression-free rates were 0.94, 0.85, and 0.67, respectively. A total of 73.7% of patients remained active. Conclusion: In the early stages of Kawasaki disease, patients with giant coronary aneurysms often experience major cardiovascular events; however, they are also likely to have normalisation of the coronary internal luminal diameter. With long-term anticoagulation, close cardiologic monitoring, and prompt thrombolytic therapy, most patients can achieve disease-free periods.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Fred发布了新的文献求助10
1秒前
天天快乐应助啊懂采纳,获得10
1秒前
活力的采枫完成签到,获得积分10
2秒前
纪清月完成签到,获得积分10
2秒前
QIAN完成签到,获得积分10
3秒前
打打应助fff采纳,获得10
3秒前
毛耳朵发布了新的文献求助10
3秒前
万能图书馆应助大壮采纳,获得10
4秒前
积极丹南发布了新的文献求助10
4秒前
苗条大发布了新的文献求助10
4秒前
爆米花应助俗人采纳,获得10
4秒前
英姑应助好好学习采纳,获得10
5秒前
5秒前
5秒前
量子星尘发布了新的文献求助10
6秒前
6秒前
orixero应助奔奔采纳,获得10
7秒前
蓁蓁完成签到,获得积分10
7秒前
gyq完成签到,获得积分10
8秒前
七月流火完成签到,获得积分10
8秒前
8秒前
8秒前
zzz发布了新的文献求助10
8秒前
8秒前
天天快乐应助科研通管家采纳,获得20
9秒前
科目三应助科研通管家采纳,获得10
9秒前
情怀应助欻欻欻采纳,获得10
9秒前
9秒前
领导范儿应助科研通管家采纳,获得10
9秒前
桐桐应助科研通管家采纳,获得10
9秒前
科研通AI6应助科研通管家采纳,获得10
9秒前
完美世界应助科研通管家采纳,获得10
9秒前
SciGPT应助科研通管家采纳,获得10
9秒前
传奇3应助科研通管家采纳,获得10
10秒前
田様应助科研通管家采纳,获得10
10秒前
上官若男应助科研通管家采纳,获得10
10秒前
科研通AI6应助科研通管家采纳,获得10
10秒前
NexusExplorer应助科研通管家采纳,获得10
10秒前
羽霜应助科研通管家采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Reproduction Third Edition 3000
《药学类医疗服务价格项目立项指南(征求意见稿)》 1000
花の香りの秘密―遺伝子情報から機能性まで 800
1st Edition Sports Rehabilitation and Training Multidisciplinary Perspectives By Richard Moss, Adam Gledhill 600
nephSAP® Nephrology Self-Assessment Program - Hypertension The American Society of Nephrology 500
Digital and Social Media Marketing 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5625139
求助须知:如何正确求助?哪些是违规求助? 4710965
关于积分的说明 14953364
捐赠科研通 4779073
什么是DOI,文献DOI怎么找? 2553598
邀请新用户注册赠送积分活动 1515504
关于科研通互助平台的介绍 1475786